11/15
01:00 pm
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
01:00 pm
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
10:52 am
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
10:52 am
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
10:27 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
11/15
09:41 am
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
08:21 am
asnd
Rating for ASND
Low
Report
Rating for ASND
11/15
08:17 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
11/15
08:17 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $181.00 price target on the stock.
11/6
06:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/6
06:32 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at Wedbush to a "strong-buy" rating.
11/4
09:31 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $170.00 price target on the stock.
11/4
08:41 am
asnd
Rating for ASND
Low
Report
Rating for ASND
10/23
07:49 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
11:41 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
11:41 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
11:20 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
11:20 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
10:05 am
asnd
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $190.00 price target on the stock, up previously from $180.00.
Medium
Report
Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $190.00 price target on the stock, up previously from $180.00.
9/17
09:56 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
09:49 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
09:49 am
asnd
Rating for ASND
Low
Report
Rating for ASND
9/17
09:25 am
asnd
Rating for ASND
Medium
Report
Rating for ASND
9/17
09:25 am
asnd
Rating for ASND
Medium
Report
Rating for ASND
9/17
09:25 am
asnd
Rating for ASND
Medium
Report
Rating for ASND